S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
The 3-Stock Retirement Blueprint (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
The 3-Stock Retirement Blueprint (Ad)
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
The 3-Stock Retirement Blueprint (Ad)
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
The 3-Stock Retirement Blueprint (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
The 3-Stock Retirement Blueprint (Ad)
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
The 3-Stock Retirement Blueprint (Ad)
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
The 3-Stock Retirement Blueprint (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
The 3-Stock Retirement Blueprint (Ad)
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
The 3-Stock Retirement Blueprint (Ad)
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
The 3-Stock Retirement Blueprint (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
The 3-Stock Retirement Blueprint (Ad)
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
The 3-Stock Retirement Blueprint (Ad)
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
ETR:EVT

Evotec - EVT Stock Forecast, Price & News

€18.17
-0.98 (-5.12%)
(As of 10/5/2022 12:00 AM ET)
Add
Compare
Today's Range
€18.00
€19.40
50-Day Range
€17.34
€29.09
52-Week Range
€17.19
€45.47
Volume
372,571 shs
Average Volume
1.36 million shs
Market Capitalization
$3.22 billion
P/E Ratio
454.25
Dividend Yield
N/A
Price Target
€37.83
EVT stock logo

About Evotec (ETR:EVT) Stock

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Receive EVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter.

EVT Stock News Headlines

Adapsyn Bioscience enters into strategic collaboration with Evotec
DGAP-News: Evotec completes acquisition of Rigenerand
DGAP-News: Evotec SE reports results of Annual General Meeting 2022
See More Headlines
Receive EVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter.

EVT Company Calendar

Today
10/05/2022
Next Earnings (Estimated)
11/09/2022

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
4,081
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
€37.83
High Stock Price Forecast
€47.00
Low Stock Price Forecast
€30.00
Forecasted Upside/Downside
+108.2%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$683.61 million
Cash Flow
€5.23 per share
Book Value
€7.22 per share

Miscellaneous

Free Float
N/A
Market Cap
$3.22 billion
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. Werner Lanthaler M.B.A. (Age 54)
    MBA, MPA, Ph.D., Chairman of Management Board & CEO
    Comp: $1.3M
  • Mr. Enno Spillner (Age 52)
    CFO & Member of Management Board
    Comp: $604k
  • Dr. Cord Dohrmann Ph.D. (Age 58)
    Chief Scientific Officer & Member of Management Board
    Comp: $726k
  • Dr. Craig Johnstone (Age 52)
    COO & Member of Management Board
    Comp: $616k
  • Dr. Matthias Evers (Age 49)
    Chief Bus. Officer & Member of Management Board
  • Ms. Anja Bosler
    Principal Accounting Officer and Sr. VP of Group Accounting
  • Mr. Volker Braun
    Sr. VP and Global Head of Investor Relations & ESG
  • Dr. Christian Dargel
    EVP Global Head of Legal & Compliance
  • Gabriele Hansen
    Sr. VP & Head of Global Corp. Communications & Marketing
  • Ms. Monika Conradt
    Global Head of HR













EVT Stock - Frequently Asked Questions

What is Evotec's stock price forecast for 2022?

0 analysts have issued 12-month price targets for Evotec's shares. Their EVT share price forecasts range from €30.00 to €47.00. On average, they predict the company's share price to reach €37.83 in the next year. This suggests a possible upside of 97.6% from the stock's current price.
View analysts price targets for EVT
or view top-rated stocks among Wall Street analysts.

How have EVT shares performed in 2022?

Evotec's stock was trading at €42.50 on January 1st, 2022. Since then, EVT shares have decreased by 54.9% and is now trading at €19.15.
View the best growth stocks for 2022 here
.

When is Evotec's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our EVT earnings forecast
.

What other stocks do shareholders of Evotec own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evotec investors own include Agilent Technologies (A), AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD), Anthem (ANTM), AxoGen (AXGN), Bank of America (BAC), Booz Allen Hamilton (BAH), Biohaven Pharmaceutical (BHVN), Biogen (BIIB) and Blueprint Medicines (BPMC).

What is Evotec's stock symbol?

Evotec trades on the ETR under the ticker symbol "EVT."

What is Evotec's stock price today?

One share of EVT stock can currently be purchased for approximately €19.15.

How much money does Evotec make?

Evotec (ETR:EVT) has a market capitalization of $3.39 billion and generates $683.61 million in revenue each year.

How many employees does Evotec have?

The company employs 4,081 workers across the globe.

How can I contact Evotec?

Evotec's mailing address is Essener Bogen 7, HAMBURG, 22419, Germany. The official website for the company is www.evotec.com. The company can be reached via phone at +49-40-560810.

This page (ETR:EVT) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.